• Explore /
  • Poster
  • / CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.

CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.

Abstract Video & Slides Poster

Authors

Shaji Kumar

Shaji Kumar

Mayo Clinic, Rochester, MN

Shaji Kumar , Carlos R. Bachier , Michele Cavo , Paolo Corradini , Michel Delforge , Wojt Janowski , Alexander M. Lesokhin , Roberto Mina , Laura Paris , Laura Rosiñol , HANG QUACH , Grant R. Goodman , Rin Nakamura , Divya Samineni , Vallari Shah , Elisabeth Wassner Fritsch , Jesus G. Berdeja

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT05535244

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS8064)

DOI

10.1200/JCO.2023.41.16_suppl.TPS8064

Abstract #

TPS8064

Poster Bd #

55b

Abstract Disclosures

Similar Posters

First Author: Xuewen Ma

First Author: Benjamin L. Schlechter

First Author: Mingyuan Sun

First Author: Dagmar Hess